MarketCap
Facebook
X
Telegram
EyePoint Pharmaceuticals Income Statement 2025-2009 | EYPT
Brief overview of financial performance at EyePoint Pharmaceuticals
The overview follows changes across a five-year period. According to figures from EyePoint Pharmaceuticals, revenue changed from 34.4 million dollars to 31.4 million dollars over five years. Overall revenue changed by −8.9%, equal to an annualized rate of about −1.8%. The revenue trend is close to stagnation.
The five-year EBITDA result moved by −592.3%: from −34.8 million dollars to −241 million dollars. Operating performance weakened relative to revenue. At the operating-margin level, the figure shifted from −101.1% to −768.6%. Cost pressure reduced operating profitability.
The net financial result changed from −45.4 million dollars to −232 million dollars. The loss widened and increased the financial risk.
The market value of the business moved from $144 million to $1.2 million, or −99.2%. Investors responded cautiously to the improvement in the business.
Overall conclusion
The current trajectory does not yet confirm a sustainable recovery. The most visible risks are weaker operating efficiency, a weaker final result and weak sales momentum. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement EyePoint Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
1.15 M | 382 K | 948 K | 92.9 M | 352 M | 144 M | 196 M | 104 M | 42.4 M | 121 M | 119 M | 124 M | 85.7 M | 61.1 M | 91.6 M | 672 M | - |
Shares |
73.3 K | 56.3 K | 38.9 K | 37.3 M | 28.8 M | 12.8 M | 10.4 M | 4.62 M | 3.53 M | 3.16 M | 2.94 M | 2.74 M | 2.3 M | 2.08 M | 1.95 M | 18.4 M | - |
Historical Prices |
15.7 | 6.79 | 24.4 | 2.49 | 12.2 | 6.58 | 15.5 | 18.9 | 10.8 | 17.1 | 48.2 | 41.1 | 39.7 | 12.1 | 11.1 | 36.5 | 20.1 |
Net Income |
-232 M | -131 M | -70.8 M | -102 M | -58.4 M | -45.4 M | -56.8 M | -53.2 M | -18.5 M | -21.5 M | 6.35 M | -13.4 M | -11.9 M | -24.8 M | -8.63 M | -2.7 M | - |
Revenue |
31.4 M | 43.3 M | 46 M | 41.4 M | 36.9 M | 34.4 M | 20.4 M | 2.96 M | 7.54 M | 1.62 M | 26.6 M | 3.47 M | 2.14 M | 3.53 M | 4.96 M | 414 K | - |
Gross Profit |
- | - | - | - | - | 28.6 M | 17.7 M | - | - | - | 26.6 M | 3.47 M | 2.14 M | 3.53 M | 4.96 M | - | - |
Operating Income |
-243 M | -146 M | -75.1 M | -99.6 M | -55.3 M | -37.3 M | -47.9 M | -39 M | -18.6 M | -21.8 M | 6.42 M | -13.5 M | -12 M | -25.2 M | -10 M | -3.12 M | - |
Interest Expense |
11.8 M | 15.1 M | 1.25 M | 3.19 M | 5.5 M | 7.26 M | 6.18 M | 2.36 M | - | - | 22 K | 5 K | -2 K | -1 K | -13 K | -3 K | - |
EBITDA |
-241 M | -144 M | -74.6 M | -99.2 M | -55 M | -34.8 M | -45.4 M | -25.1 M | -17.8 M | -20.9 M | 7.3 M | -12.7 M | -11 M | -8.15 M | -6.65 M | -3.08 M | - |
Operating Expenses |
275 M | 189 M | 121 M | 141 M | 92.2 M | 65.9 M | 65.5 M | 29.2 M | 26.1 M | 23.4 M | 20.1 M | 17 M | 14.2 M | 13.9 M | 15 M | 14 M | - |
General and Administrative Expenses |
51.6 M | 52.4 M | 40.1 M | 34.8 M | 25.6 M | 20.7 M | 17.9 M | 11.5 M | 11.2 M | 9.01 M | 8.06 M | 7.47 M | 7.17 M | 6.87 M | 8.1 M | 6.97 M | - |
All numbers in USD currency
Quarterly Income Statement EyePoint Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
86.5 K | 86 K | 70.2 K | 69.9 K | 69.8 M | 68.3 M | 54.4 K | 53.2 K | 52.9 M | 49 M | 38.3 M | 37.6 M | 37.5 M | 34.1 M | 37.3 M | 37.3 M | 37.3 M | 33.9 M | 28.8 M | 28.7 M | 24.7 M | 18.1 M | 12.8 M | 12.5 M | 11.6 M | 107 M | 107 M | 106 M | 95.5 M | 94.5 M | 75.2 M | 55.4 M | 75.2 M | 44.5 M | 39.4 M | 44.5 M | 39.4 M | 34.2 M | 34.2 M | 34.2 M | 33.5 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 29.3 M | 29.4 M | 29.3 M | 27 M | 25.9 M | 27 M | 25.9 M | 23.3 M | 22.3 M | 23.3 M | 22.3 M | 20.8 M | 20.8 M | 20.7 M | 20.2 M |
Net Income |
-94.5 M | -84.8 M | -59.7 M | -59.4 M | -45.2 M | - | -29.4 M | -30.8 M | -29.3 M | - | -12.6 M | -22.9 M | -21.2 M | - | -18.4 M | -19.4 M | -21 M | - | -16.7 M | -10 M | -12.3 M | - | -3.8 M | -13 M | -13.2 M | -10.4 M | -15.6 M | -11.5 M | -19.2 M | -11.6 M | -33.1 M | -34.4 M | -33.1 M | -5.78 M | -5.98 M | -5.78 M | -5.98 M | -67 K | -7.16 M | -67 K | -7.16 M | -5.19 M | -4.93 M | -5.19 M | -4.93 M | -4.08 M | 20.6 M | -4.08 M | 20.6 M | -3.51 M | -3.69 M | -3.51 M | -3.69 M | -2.61 M | -2.55 M | -2.61 M | -2.55 M | -17.5 M | -2.43 M | -17.5 M | -2.43 M |
Revenue |
507 K | 696 K | 966 K | 5.33 M | 24.5 M | - | 10.5 M | 9.48 M | 11.7 M | - | 15.2 M | 9.1 M | 7.68 M | - | 10 M | 11.6 M | 9.29 M | - | 9.06 M | 9.01 M | 7.32 M | - | 15.7 M | 4.12 M | 7.49 M | 8.63 M | 2.51 M | 7.21 M | 2.01 M | 2.44 M | 486 K | 715 K | 928 K | 933 K | 385 K | 1.32 M | 590 K | 5.97 M | 277 K | 5.97 M | 277 K | 526 K | 466 K | 526 K | 466 K | 521 K | 25.3 M | 521 K | 25.3 M | 592 K | 597 K | 592 K | 597 K | 585 K | 553 K | 585 K | 553 K | 630 K | 1.66 M | 630 K | 1.66 M |
Cost of Revenue |
- | - | - | - | - | - | 736 K | 1.4 M | - | - | 1.2 M | 1.79 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 706 K | 330 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-97.4 M | -87.2 M | -62 M | -62.2 M | -48.8 M | - | -32.7 M | -34.5 M | -33.3 M | - | -14.4 M | -22.8 M | -21.6 M | - | -18.4 M | -19.2 M | -18.3 M | - | -15.3 M | -11 M | -10.9 M | - | -1.96 M | -11.2 M | -11.4 M | -8.98 M | -14.1 M | -10.2 M | -14.7 M | -11 M | -13.6 M | -9.78 M | -13.6 M | -5.81 M | -6.01 M | -5.81 M | -6.01 M | -94 K | -7.19 M | -94 K | -7.19 M | -5.24 M | -4.98 M | -5.24 M | -4.98 M | -4.12 M | 20.8 M | -4.12 M | 20.8 M | -3.54 M | -3.72 M | -3.54 M | -3.72 M | -2.65 M | -2.59 M | -2.65 M | -2.59 M | -17.6 M | -2.53 M | -17.6 M | -2.53 M |
Interest Expense |
2.91 M | 2.34 M | 2.29 M | 2.89 M | 3.64 M | - | 3.39 M | 3.72 M | 4.04 M | - | - | 435 K | 812 K | - | 662 K | 552 K | 1.19 M | - | 1.39 M | 1.38 M | 1.35 M | - | 1.84 M | 1.81 M | 1.78 M | - | 1.77 M | 1.6 M | 1.02 M | - | 815 K | 720 K | 815 K | 26 K | - | 49 K | 23 K | 27 K | 24 K | 27 K | 24 K | 10 K | 10 K | 10 K | 10 K | 3 K | 3 K | - | - | - | -2 K | - | - | -1 K | -1 K | -1 K | -1 K | - | -2 K | -2 K | -2 K |
EBITDA |
-96.1 M | -86.6 M | -61.4 M | -61.7 M | -48.3 M | - | -32.3 M | -34.2 M | -33 M | - | - | - | -21.4 M | - | -17.8 M | -19.2 M | -18.2 M | - | -15.1 M | -10.4 M | -10.9 M | - | -1.82 M | -11.1 M | -11.4 M | -8.98 M | -14 M | -10.1 M | -14.6 M | -11 M | -13.5 M | -9.7 M | -13.5 M | -5.62 M | -5.97 M | -5.72 M | -5.97 M | 86 K | -7.18 M | -62 K | -7.18 M | -5.05 M | -4.96 M | -5.18 M | -4.96 M | -3.92 M | 20.8 M | -4.06 M | 20.8 M | -3.35 M | -3.68 M | -3.47 M | -3.68 M | -2.45 M | -2.54 M | -2.54 M | -2.54 M | -16.8 M | -2.51 M | -17.6 M | -2.51 M |
Operating Expenses |
97.9 M | 87.9 M | 63 M | 67.6 M | 73.3 M | - | 43.3 M | 44 M | 45 M | - | 29.6 M | 31.9 M | 29.2 M | - | 28.4 M | 30.8 M | 27.6 M | - | 24.4 M | 20 M | 18.3 M | - | 17.7 M | 15.3 M | 18.9 M | - | 16.6 M | 17.4 M | 16.7 M | - | 14 M | 10.5 M | 14 M | 6.74 M | 6.39 M | 13.1 M | 6.39 M | 6.06 M | 7.46 M | 6.06 M | 7.46 M | 5.76 M | 5.45 M | 5.76 M | 5.45 M | 4.64 M | 4.52 M | 4.64 M | 4.52 M | 4.13 M | 4.32 M | 4.13 M | 4.32 M | 3.23 M | 3.14 M | 3.23 M | 3.14 M | 18.3 M | 4.19 M | 18.3 M | 4.19 M |
General and Administrative Expenses |
14.2 M | 15.2 M | 14.5 M | 11.9 M | 13.9 M | - | 13 M | 12.8 M | 14.1 M | - | 10.6 M | 9.06 M | 9.24 M | - | 9.21 M | 8.56 M | 8.55 M | - | 6.06 M | 5.18 M | 5.12 M | - | 5.8 M | 4.79 M | 4.36 M | - | 4.36 M | 4.82 M | 4.61 M | - | 4.16 M | 4.22 M | 4.16 M | 2.47 M | 2.57 M | 5.04 M | 2.57 M | 2.9 M | 3.28 M | 2.9 M | 3.28 M | 2.04 M | 1.97 M | 2.04 M | 1.97 M | 1.87 M | 1.73 M | 1.87 M | 1.73 M | 1.71 M | 1.81 M | 1.71 M | 1.81 M | 1.66 M | 1.62 M | 1.66 M | 1.62 M | 1.45 M | 2.06 M | 1.45 M | 2.06 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company EyePoint Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
Israel
Britain
Singapore
USA
China
Japan
Canada